Show simple item record

hal.structure.identifierLaboratoire d'Economie de Dauphine [LEDa]
dc.contributor.authorDegrassat-Théas, Albane*
hal.structure.identifierLaboratoire d'Economie de Dauphine [LEDa]
dc.contributor.authorLe Pen, Claude*
hal.structure.identifier
dc.contributor.authorParent de Curzon, Olivier*
hal.structure.identifier
dc.contributor.authorPaubel, Pascal*
hal.structure.identifier
dc.contributor.authorPoisson, N.*
hal.structure.identifier
dc.contributor.authorSinègre, Martine*
dc.date.accessioned2013-04-29T14:02:20Z
dc.date.available2013-04-29T14:02:20Z
dc.date.issued2012
dc.identifier.issn1098-3015
dc.identifier.urihttps://basepub.dauphine.fr/handle/123456789/11271
dc.descriptionISPOR 15th Annual European Congress, 11-2012, Berlin, Allemagne
dc.language.isoenen
dc.subjectrare disease market
dc.subjectorphan drugs
dc.subjectcost
dc.subject.ddc334en
dc.subject.classificationjelI11en
dc.titleIs Orphan Designation a Driver of Orphan Drug Pricing?
dc.typeArticle accepté pour publication ou publié
dc.description.abstractenObjectivesPolicy makers pay more and more attention to the orphan drug market. Pharmaceutical companies are suspected to take advantage of the legislation. Moreover, granted an orphan designation (OD) could be associated with higher prices. The aim of this work is to assess the impact of the current European orphan drug legislation on prices within the rare disease market of the largest University Medical Center in France (AP-HP).MethodsWe included all drugs with exclusively rare disease indications, with or without (control group) European OD prior to European marketing authorization. We collected 2011 AP-HP prices and additional characteristics: prevalence of rare diseases; alternative drug existence and improvement in medical benefit (ASMR) assessed by the French National Authority for Health (HAS).ResultsFrom drugs indicated for rare diseases available in AP-HP, we retrieved those for which all additional characteristics were documented: 41 drugs with OD, 17 without OD. The contribution to the growth of the overall drug expenditures in AP-HP reached 1.16 points out of 3.40 points for OD drugs (99% of growth was explained by 3 drugs) and 0.39 for non OD drugs. No statistically significant difference in the price distribution was found between OD drugs (median: €180.4; interquartile range: €679.9) and non OD drugs (median: €443.9; interquartile range: €1433.1) (p=0.19). The price distributions were scattered (standard deviation: 1040.2 and 3512.1 respectively). Other characteristics between the two groups were not statistically different.ConclusionsConcerns on the growing budgetary pressure of orphan drugs may affect social solidarity, and yet this study underlines the heterogeneity of the rare disease market. From these study results, OD approval should not be considered as the only price inflation cause. If the legislation should be adapted to limit windfall effects for pharmaceutical companies, the support of innovation in a fairness and egalitarian way is needed.
dc.relation.isversionofjnlnameValue in Health
dc.relation.isversionofjnlvol15
dc.relation.isversionofjnlissue7
dc.relation.isversionofjnldate2012
dc.relation.isversionofjnlpagesA302
dc.relation.isversionofdoihttp://dx.doi.org/10.1016/j.jval.2012.08.617
dc.relation.isversionofjnlpublisherElsevier
dc.subject.ddclabelEconomie socialeen
dc.relation.forthcomingnonen
dc.description.ssrncandidatenon
dc.description.halcandidateoui
dc.description.readershiprecherche
dc.description.audienceInternational
dc.relation.Isversionofjnlpeerreviewedoui
dc.date.updated2017-12-22T12:32:06Z
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut
hal.author.functionaut


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record